Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1957
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1968 2
1969 1
1972 1
1974 3
1979 1
1986 2
1987 2
1988 3
1989 2
1990 3
1991 2
1992 2
1993 4
1994 5
1995 3
1996 5
1997 3
1998 3
1999 3
2000 5
2001 3
2002 8
2003 5
2004 7
2005 11
2006 18
2007 11
2008 17
2009 21
2010 14
2011 22
2012 16
2013 11
2014 5
2015 8
2016 12
2017 14
2018 15
2019 10
2020 14
2021 21
2022 20
2023 25
2024 22
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

351 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial.
Ezzedine K, Peeva E, Yamaguchi Y, Cox LA, Banerjee A, Han G, Hamzavi I, Ganesan AK, Picardo M, Thaçi D, Harris JE, Bae JM, Tsukamoto K, Sinclair R, Pandya AG, Sloan A, Yu D, Gandhi K, Vincent MS, King B. Ezzedine K, et al. Among authors: cox la. J Am Acad Dermatol. 2023 Feb;88(2):395-403. doi: 10.1016/j.jaad.2022.11.005. Epub 2022 Nov 9. J Am Acad Dermatol. 2023. PMID: 36370907 Free article. Clinical Trial.
Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers.
Guttman-Yassky E, Pavel AB, Diaz A, Zhang N, Del Duca E, Estrada Y, King B, Banerjee A, Banfield C, Cox LA, Dowty ME, Page K, Vincent MS, Zhang W, Zhu L, Peeva E. Guttman-Yassky E, et al. Among authors: cox la. J Allergy Clin Immunol. 2022 Apr;149(4):1318-1328. doi: 10.1016/j.jaci.2021.10.036. Epub 2021 Dec 1. J Allergy Clin Immunol. 2022. PMID: 34863853 Free article. Clinical Trial.
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, Zhu L, Cox LA, Craiglow B, Chen L, Banfield C, Page K, Zhang W, Vincent MS. King B, et al. Among authors: cox la. J Am Acad Dermatol. 2021 Aug;85(2):379-387. doi: 10.1016/j.jaad.2021.03.050. Epub 2021 Mar 20. J Am Acad Dermatol. 2021. PMID: 33757798 Free article. Clinical Trial.
Response.
Aven T, Cox LA Jr. Aven T, et al. Among authors: cox la jr. Risk Anal. 2016 May;36(5):869. doi: 10.1111/risa.12628. Risk Anal. 2016. PMID: 27198874 No abstract available.
Special issue: Risk science foundations in light of COVID-19.
Aven T, Cox LA Jr, Flage R, Guikema SD, Haas CN. Aven T, et al. Among authors: cox la jr. Risk Anal. 2024 Dec;44(12):2759-2761. doi: 10.1111/risa.17686. Epub 2024 Dec 11. Risk Anal. 2024. PMID: 39663147 No abstract available.
What is an exposure-response curve?
Cox LA Jr. Cox LA Jr. Glob Epidemiol. 2023 Jun 15;6:100114. doi: 10.1016/j.gloepi.2023.100114. eCollection 2023 Dec. Glob Epidemiol. 2023. PMID: 37637716 Free PMC article.
Objective causal predictions from observational data.
Cox LA Jr. Cox LA Jr. Crit Rev Toxicol. 2024 Nov;54(10):895-924. doi: 10.1080/10408444.2024.2399856. Epub 2024 Oct 15. Crit Rev Toxicol. 2024. PMID: 39403830 Free article. Review.
Cite
351 results